Literature DB >> 8217062

The challenge of predicting response to stabilising lithium treatment. The importance of patient selection.

P Grof1, M Alda, E Grof, D Fox, P Cameron.   

Abstract

Lithium treatment, an approach with well documented efficacy, has recently been losing its treatment value. Lithium continues working, however, for those patients for whom it was proven efficacious; that is, most patients with primary episodic affective disorders. Such responders to lithium prophylaxis can be reliably identified beforehand by a comprehensive clinical assessment. The explanation for the paradox of lithium's lost efficacy lies mostly in the educational bias against a comprehensive patient assessment, and in the shift in diagnostic fashion favouring affective disorders and the treatment methods associated with them in the clinicians' minds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217062

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  16 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

4.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 5.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

6.  The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review.

Authors:  U Lewitzka; E Severus; R Bauer; P Ritter; B Müller-Oerlinghausen; M Bauer
Journal:  Int J Bipolar Disord       Date:  2015-07-18

7.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31

8.  Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?

Authors:  Michael Berger; Michael Riedel; Nora Tomova; Michael Obermeier; Florian Seemüller; Sandra Dittmann; Hans-Jürgen Moeller; Emanuel Severus
Journal:  Int J Bipolar Disord       Date:  2013-06-14

9.  Lithium: a key to the genetics of bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Gustavo Turecki
Journal:  Genome Med       Date:  2009-08-19       Impact factor: 11.117

10.  Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report.

Authors:  Mirko Manchia; Mazda Adli; Nirmala Akula; Raffaella Ardau; Jean-Michel Aubry; Lena Backlund; Claudio Em Banzato; Bernhard T Baune; Frank Bellivier; Susanne Bengesser; Joanna M Biernacka; Clara Brichant-Petitjean; Elise Bui; Cynthia V Calkin; Andrew Tai Ann Cheng; Caterina Chillotti; Sven Cichon; Scott Clark; Piotr M Czerski; Clarissa Dantas; Maria Del Zompo; J Raymond Depaulo; Sevilla D Detera-Wadleigh; Bruno Etain; Peter Falkai; Louise Frisén; Mark A Frye; Jan Fullerton; Sébastien Gard; Julie Garnham; Fernando S Goes; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Urs Heilbronner; Rebecca Hoban; Liping Hou; Stéphane Jamain; Jean-Pierre Kahn; Layla Kassem; Tadafumi Kato; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Po-Hsiu Kuo; Ichiro Kusumi; Gonzalo Laje; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Carlos A López Jaramillo; Mario Maj; Alain Malafosse; Lina Martinsson; Takuya Masui; Philip B Mitchell; Frank Mondimore; Palmiero Monteleone; Audrey Nallet; Maria Neuner; Tomás Novák; Claire O'Donovan; Urban Osby; Norio Ozaki; Roy H Perlis; Andrea Pfennig; James B Potash; Daniela Reich-Erkelenz; Andreas Reif; Eva Reininghaus; Sara Richardson; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Oliver K Schubert; Barbara Schweizer; Florian Seemüller; Maria Grigoroiu-Serbanescu; Giovanni Severino; Lisa R Seymour; Claire Slaney; Jordan W Smoller; Alessio Squassina; Thomas Stamm; Jo Steele; Pavla Stopkova; Sarah K Tighe; Alfonso Tortorella; Gustavo Turecki; Naomi R Wray; Adam Wright; Peter P Zandi; David Zilles; Michael Bauer; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Martin Alda
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.